Literature DB >> 2513475

Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway.

S Pellegrini1, J John, M Shearer, I M Kerr, G R Stark.   

Abstract

We have selected mutations in genes encoding components of the signaling pathway for alpha interferon (IFN-alpha) by using a specially constructed cell line. The upstream region of the IFN-regulated human gene 6-16 was fused to the Escherichia coli guanine phosphoribosyltransferase (gpt) gene and transfected into hypoxanthine-guanine phosphoribosyltransferase-negative human cells. These cells express gpt only in the presence of IFN-alpha. They grow in medium containing hypoxanthine, aminopterin, and thymidine plus IFN and are killed by 6-thioguanine plus IFN. Two different types of mutants were obtained after treating the cells with mutagens. A recessive mutant, selected in 6-thioguanine plus IFN, was completely resistant to IFN-alpha but responded normally to IFN-gamma and, unexpectedly, partially to IFN-beta. A constitutive mutant, selected in hypoxanthine-aminopterin-thymidine alone, was abnormal in expressing endogenous genes in the absence of IFN. Both types revert infrequently, allowing selection for complementation of the defects by transfection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513475      PMCID: PMC363606          DOI: 10.1128/mcb.9.11.4605-4612.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

1.  Phenotypic switching in cells transformed with the herpes simplex virus thymidine kinase gene.

Authors:  M Ostrander; S Vogel; S Silverstein
Journal:  Mol Cell Biol       Date:  1982-06       Impact factor: 4.272

2.  Loss of mouse chromosomes in somatic cell hybrids between HT-1080 human fibrosarcoma cells and mouse peritioneal macrophages.

Authors:  C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

3.  Analyses of mutation in pSV2gpt-transformed CHO cells.

Authors:  K R Tindall; L F Stankowski; R Machanoff; A W Hsie
Journal:  Mutat Res       Date:  1986-04       Impact factor: 2.433

4.  Characterization of a newly derived human sarcoma cell line (HT-1080).

Authors:  S Rasheed; W A Nelson-Rees; E M Toth; P Arnstein; M B Gardner
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

5.  Interferon and cell division. IX. Interferon-resistant L1210 cells: characteristics and origin.

Authors:  I Gresser; M T Bandu; D Brouty-Boyé
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

6.  Spontaneous and ICR191-A-induced frameshift mutations in the A gene of Escherichia coli tryptophan synthetase.

Authors:  H Berger; W J Brammar; C Yanofsky
Journal:  J Bacteriol       Date:  1968-11       Impact factor: 3.490

7.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

8.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

9.  High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor.

Authors:  M Aguet
Journal:  Nature       Date:  1980-04-03       Impact factor: 49.962

10.  Comparative mutagenicity of ICR-191 to S. typhimurium and diploid human lymphoblasts.

Authors:  J G Deluca; D A Kaden; J Krolewski; T R Skopek; W G Thilly
Journal:  Mutat Res       Date:  1977-02-01       Impact factor: 2.433

View more
  122 in total

1.  Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.

Authors:  R M Arduini; K L Strauch; L A Runkel; M M Carlson; X Hronowski; S F Foley; C N Young; W Cheng; P S Hochman; D P Baker
Journal:  Protein Sci       Date:  1999-09       Impact factor: 6.725

2.  A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling.

Authors:  T C Yeh; E Dondi; G Uze; S Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

3.  Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection.

Authors:  G Gao; S P Goff
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

4.  A new method for the selection of protein interactions in mammalian cells.

Authors:  E Rojo-Niersbach; D Morley; S Heck; N Lehming
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

5.  Mutant human cells with constitutive activation of NF-kappaB.

Authors:  Swati S Sathe; Nywana Sizemore; Xiaoxia Li; Kalpa Vithalani; Mairead Commane; Shannon M Swiatkowski; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-22       Impact factor: 11.205

6.  Virus replication in engineered human cells that do not respond to interferons.

Authors:  D F Young; L Andrejeva; A Livingstone; S Goodbourn; R A Lamb; P L Collins; R M Elliott; R E Randall
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 7.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

Review 8.  Use of forward genetics to discover novel regulators of NF-kappaB.

Authors:  Tao Lu; George R Stark
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-23       Impact factor: 10.005

9.  Cofilin 1 is revealed as an inhibitor of glucocorticoid receptor by analysis of hormone-resistant cells.

Authors:  Joëlle Rüegg; Florian Holsboer; Christoph Turck; Theo Rein
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

10.  Involvement of the transcription factor PU.1/Spi-1 in myeloid cell-restricted expression of an interferon-inducible gene encoding the human high-affinity Fc gamma receptor.

Authors:  C Perez; E Coeffier; F Moreau-Gachelin; J Wietzerbin; P D Benech
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.